Business Context and Reporting Period
Company: Microbot Medical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2026
Reporting Period: Event-based report for March 26, 2026.
This filing discloses a strategic milestone regarding the Company's LIBERTY® Endovascular Robotic System. On March 26, 2026, Microbot Medical Inc. issued a joint press release with Emory Healthcare announcing the successful completion of robotic peripheral endovascular procedures using the LIBERTY System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific operational event and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the expansion of clinical applications for the LIBERTY System at Emory Healthcare. Specifically:
- Emory Healthcare successfully completed robotic peripheral endovascular procedures (minimally invasive treatments for vascular conditions).
- Emory interventional radiologists demonstrated successful use of the system for benign prostatic hyperplasia (BPH).
- Emory interventional radiologists demonstrated successful use of the system for liver cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the versatility of the LIBERTY System across different medical conditions, including vascular conditions, BPH, and liver cancer, as demonstrated by Emory Healthcare.
Risks and Contingencies: The filing explicitly states that the information in Item 7.01 and the accompanying press release (Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this report is not an admission as to the materiality of the information provided.
Guidance: No forward-looking financial guidance or specific outlook metrics are provided in this text.
Investor Verification Checklist
- Verify the full text of the joint press release (Exhibit 99.1) for specific details on the procedures performed.
- Confirm whether the successful procedures at Emory Healthcare lead to immediate commercial agreements or reimbursement approvals.
- Review subsequent filings for any financial impact or revenue recognition related to these new clinical applications.
- Assess the regulatory status of the LIBERTY System for the newly demonstrated indications (BPH and liver cancer).